Wegovy after 3 months: what the evidence actually shows

What the trial data says about results at this stage

The STEP 1 trial is the most cited evidence base for Wegovy's effectiveness: 68 weeks, roughly 1,960 adults with obesity or overweight plus a weight-related condition, against placebo alongside lifestyle changes. Average weight loss at the end of the full trial was around 15% of body weight at the 2.4mg dose. But that headline figure reflects nearly a year and a half of treatment.

At three months specifically, participants were generally approaching or completing titration, the graduated dose-increase schedule that takes you from 0.25mg up through 0.5mg, 1.0mg and 1.7mg before reaching 2.4mg. Weight loss at this stage tends to sit in the 6–8% range on average, with some people seeing more and some less. The curve steepens once the maintenance dose is established, which is why three months often feels like the beginning of the more significant phase rather than the end of it.

A practical check worth doing: weigh yourself on the same scales, at the same time of day, once a week. A single weigh-in tells you almost nothing; a four-week trend tells you something real. If the numbers are moving in the right direction, even slowly, that's clinically meaningful. If they're not moving at all, that's worth raising with your prescriber before the next review.

You can read more about what to expect at the two-month mark to understand how the earlier weeks compare, and what the picture looks like at six months for the longer-term trajectory.

Side effects at three months, what's usually changing

Nausea, the most common complaint on semaglutide, tends to peak when a dose step happens and then settle over the following one to two weeks. By month three, most people have been through several of those cycles and find the discomfort noticeably less acute than it was at the start.

That said, side effects don't disappear uniformly. Some people still experience nausea at 1.7mg or 2.4mg, particularly in the first week after a new dose. Constipation, reflux and a reduced appetite often persist, though many find the appetite reduction is exactly what they were hoping for. The NHS semaglutide medicines guide lists the full side effect profile and, importantly, the symptoms that warrant prompt medical attention, severe, persistent abdominal pain is one to take seriously and discuss with a doctor or call 111 if it comes on suddenly.

Injection-site reactions (mild redness or itching at the spot) can linger for some people. Rotating the site between your abdomen, thigh and upper arm each week helps. If you have questions about technique or a reaction that seems more than mild, your prescriber or the Patient Information Leaflet are the right places to go.

Is three months long enough to judge whether Wegovy is working?

This is a question our prescribers hear regularly. Three months is genuinely too early to conclude Wegovy isn't working, but it's not too early to assess whether your current trajectory is on track.

NICE's recommendation for semaglutide (outlined in NICE technology appraisal TA875) includes a review point at six months on the maintenance dose: if weight loss is less than 5% at that stage, continuing is reconsidered. Three months sits before that threshold, but it's a reasonable point to take stock. If you're losing weight gradually and tolerating the treatment well, continuing is usually the right call. If you've had no meaningful change and side effects are significant, there's a conversation to be had about whether the titration needs more time, whether lifestyle support needs strengthening, or whether a different approach fits better.

People sometimes wonder whether stopping at this point makes sense, there's a separate piece on stopping Wegovy at three months that covers what the evidence says about discontinuation and what happens to weight when treatment ends.

Where three months fits in the longer picture

Three months on Wegovy is, clinically speaking, the early-middle phase. You've done the hard part of titration. The maintenance dose, once established, is where the more sustained loss tends to happen, and that continues through months four, five and six before beginning to plateau for most people. Earlier losses in the first two months often feel slower; the next three months typically feel faster.

For context on where Wegovy sits among the available weight-loss treatments and how it compares in practice, the treatment overview is a useful reference. And if you're weighing up whether to continue or thinking about what happens long-term, the six-month stopping question is worth reading ahead of time.

At nume, a real prescriber (not an algorithm) reviews your progress at each repeat. If you're thinking about starting treatment or your current provider hasn't reviewed your progress properly, speaking to our prescribers is a straightforward next step. You can see how we approach clinical oversight on our about page, or start a free consultation when you're ready.